Epithelial Tissues CD 6 Ligand in Cells Derived from Joint and Expression and Characterization of a Novel and

[1]  D. Dykxhoorn,et al.  Killing the messenger: short RNAs that silence gene expression , 2003, Nature Reviews Molecular Cell Biology.

[2]  Phillip A Sharp,et al.  siRNAs can function as miRNAs , 2003 .

[3]  Michael T. McManus,et al.  Small Interfering RNA-Mediated Gene Silencing in T Lymphocytes1 , 2002, The Journal of Immunology.

[4]  V. Goldberg,et al.  Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1 beta-induced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes. , 2002, Free radical biology & medicine.

[5]  T. Suda,et al.  Mesenchymal Stem Cells in Perichondrium Express Activated Leukocyte Cell Adhesion Molecule and Participate in Bone Marrow Formation , 2002, The Journal of experimental medicine.

[6]  L. Beretta,et al.  CD6: expression during development, apoptosis and selection of human and mouse thymocytes. , 2002, International immunology.

[7]  T. Suda,et al.  ALCAM (CD166): its role in hematopoietic and endothelial development. , 2001, Blood.

[8]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[9]  J. Bajorath,et al.  Cell surface receptors and their ligands: In vitro analysis of CD6‐CD166 interactions , 2000, Proteins.

[10]  B. D. de Grooth,et al.  Dynamic regulation of activated leukocyte cell adhesion molecule-mediated homotypic cell adhesion through the actin cytoskeleton. , 2000, Molecular biology of the cell.

[11]  C. Figdor,et al.  Molecular analysis of the hematopoiesis supporting osteoblastic cell line U2-OS. , 2000, Experimental hematology.

[12]  R. Kinne,et al.  Evidence for the expression of a second CD6 ligand by synovial fibroblasts. , 2000, Arthritis and rheumatism.

[13]  J. Ritz,et al.  Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Patel,et al.  Cytokine-regulated expression of activated leukocyte cell adhesion molecule (CD166) on monocyte-lineage cells and in rheumatoid arthritis synovium. , 1998, Arthritis and rheumatism.

[15]  J. Ritz,et al.  Efficacy and costs of granulocyte colony-stimulating factor in allogeneic T-cell depleted bone marrow transplantation. , 1998, Blood.

[16]  G. Mosser,et al.  Detergent removal by non-polar polystyrene beads , 1998, European Biophysics Journal.

[17]  D. Neuberg,et al.  T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin ’ s lymphoma , 1998 .

[18]  Joseph Zaia,et al.  Mesenchymal Stem Cell Surface Antigen SB‐10 Corresponds to Activated Leukocyte Cell Adhesion Molecule and Is Involved in Osteogenic Differentiation , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  Y. van Kooyk,et al.  MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule). , 1998, The American journal of pathology.

[20]  J. Kobarg,et al.  Analysis of the tyrosine phosphorylation and calcium fluxing of human CD6 isoforms with different cytoplasmatic domains , 1997, European journal of immunology.

[21]  J. Bajorath,et al.  Characterization of mouse ALCAM (CD166): the CD6‐binding domain is conserved in different homologs and mediates cross‐species binding , 1997, European journal of immunology.

[22]  B. Nickoloff,et al.  CD6 dependent interactions of T cells and keratinocytes: functional evidence for a second CD6 ligand on gamma-interferon activated keratinocytes. , 1997, Immunology letters.

[23]  D. Fairclough,et al.  CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. , 1997, Blood.

[24]  J. Bajorath,et al.  Mutational analysis of the CD6 binding site in activated leukocyte cell adhesion molecule. , 1996, Biochemistry.

[25]  J. Bajorath,et al.  Recognition of diverse proteins by members of the immunoglobulin superfamily: delineation of the receptor binding site in the human CD6 ligand ALCAM. , 1996, Biochemistry.

[26]  D. Fox,et al.  Role of the CD6 glycoprotein in antigen-specific and autoreactive responses of cloned human T lymphocytes. , 1996, Immunology.

[27]  J. Bajorath,et al.  The Amino-terminal Immunoglobulin-like Domain of Activated Leukocyte Cell Adhesion Molecule Binds Specifically to the Membrane-proximal Scavenger Receptor Cysteine-rich Domain of CD6 with a 1:1 Stoichiometry* , 1996, The Journal of Biological Chemistry.

[28]  B. Haynes,et al.  Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand , 1995, The Journal of experimental medicine.

[29]  B. Haynes,et al.  Identification and characterization of a 100-kD ligand for CD6 on human thymic epithelial cells , 1995, The Journal of experimental medicine.

[30]  B. Haynes,et al.  Characterization of a CD6 ligand(s) expressed on human- and murine-derived cell lines and murine lymphoid tissues. , 1994, Cellular immunology.

[31]  K. O'rourke,et al.  Lymphocyte function-associated antigen 1 overexpression and T cell autoreactivity. , 1994, Arthritis and rheumatism.

[32]  S. Chow,et al.  The anti-CD6 mAb, IOR-T1, defined a new epitope on the human CD6 molecule that induces greater responsiveness in T cell receptor/CD3-mediated T cell proliferation. , 1994, Cellular immunology.

[33]  J. Daley,et al.  Isolation and characterization of CD6- T cells from peripheral blood. , 1994, Journal of immunology.

[34]  C. Morimoto,et al.  Activation of human T cells through CD6: functional effects of a novel anti-CD6 monoclonal antibody and definition of four epitopes of the CD6 glycoprotein. , 1993, International immunology.

[35]  C. Thompson,et al.  Accessory cell function of keratinocytes for superantigens. Dependence on lymphocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. , 1993, Journal of immunology.

[36]  A. Freedman,et al.  Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. , 1992, Journal of Clinical Oncology.

[37]  J. Barker,et al.  HUT 78 T cells bind to noncytokine-stimulated keratinocytes using a non-CD18-dependent adhesion pathway. , 1992, The American journal of pathology.

[38]  P. Linsley,et al.  The lymphocyte glycoprotein CD6 contains a repeated domain structure characteristic of a new family of cell surface and secreted proteins , 1991, The Journal of experimental medicine.

[39]  C. Morimoto,et al.  Structural characterization of CD6: properties of two distinct epitopes involved in T cell activation. , 1989, Molecular immunology.

[40]  J. Swack,et al.  Anti-T12, an anti-CD6 monoclonal antibody, can activate human T lymphocytes. , 1989, Journal of immunology.

[41]  W. Knapp Leucocyte typing IV : white cell differentiation antigens , 1989 .

[42]  P. Hoffman,et al.  Antibody-induced antigenic modulation is antigen dependent: characterization of 22 proteins on a malignant human B cell line. , 1986, Journal of immunology.